Summary Breast cancer screening is generally accepted as an effective means of reducing breast cancer mortality in post-menopausal women. In this analysis the impact of nationwide screening on clinical medicine and the effects for the women involved are quantified. Effect estimates are based on results from screening trials in Utrecht (DOM-project) and Nijmegen, and on bi-annual screening of women aged 50-70. The consequences for health care are based on generally accepted assessment and treatment policies. The number of assessment procedures for non-palpable lesions will increase by 12% per year in the build-up period, and will remain slightly higher. The total number of biopsies in a real population is expected to decrease. Screening will lead to a shift in primary treatment modalities, as 15% of mastectomies will be replaced by breast conserving therapy. The temporary increase in the demand for primary treatment in the first years will be followed by a decrease in the demand for treating women with advanced disease. Favourable effects outweigh the inevitable unfavourable effects, with high quality screening and an appropriate invitation system. Breast cancer screening can also be recommended after considering other consequences than mortality reduction.
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Several trials have shown that mammographic screening of post-menopausal women reduces breast cancer mortality (Shapiro et al., 1982; Verbeek et al., 1984; Collette et al., 1984; Tabar et al., 1985; UK Trial 1988; Andersson et al., 1988) . The introduction of a national programme in the United Kingdom, offering tri-annual screening to women aged 50-65, would result in a mortality reduction of 8% (Knox, 1988) . In the Netherlands with bi-annual screening of women aged 50-70, this figure would be 12% (van der Maas et al., 1989) .
Although mortality reduction is the fundamental effect (Day et al., 1989) , there is much debate about other desirable and undesirable consequences of breast cancer screening (Warren, 1988; Skrabanek, 1988) . However, publications which quantify these consequences are lacking. Starting to screen will result in a temporary increase in the number of women with newly diagnosed breast cancer. Detecting these cancers at an earlier stage will affect the type of assessment and treatment. Mass screening will also generate referrals of women, who appear to have no breast cancer (false positives) (Forrest, 1986). This report presents this impact of nationwide screening on three issues: change in referral patterns and assessment procedures; change in breast cancer incidence; and change in stage distribution and subsequent treatment. An overview is given of favourable and unfavourable effects for the women involved, and the consequences for health care.
The computations are made for the Dutch population, but the conclusions are relevant to other countries too. Predictions are made for both the first years of implementing the programme and the stable situation. Medical activities outside the programme are included. 
Assessment and excision biopsy
In assessing breast abnormalities, at least three successive steps were distinguished: physical examination, clinical mammography and excision biopsy (with possible specimen radiography). Additional possibilities which were taken into account for palpable lesions only were fine needle aspiration (cytology) and ultrasound.
Estimates of the number and type of these procedures used in the situation without screening were based on the following sources: general practitioners' registry (Trouw, 1986) ; the radioactivity and radiation application division of the Ministry of Welfare, Health and Cultural Affairs; the Central Office for the Administration of Specialists' Fees (De Waard et al., 1986) ; and the Steering Committee on Future Health Scenarios (1988) .
Estimates on the change in numbers and types of assessment when introducing mass screening were derived using the referral patterns from the Dutch screening trials (Verbeek et al., 1984; Collette et al., 1984) The following types of treatment with curative intent were distinguished: total mastectomy (dCIS); total mastectomy with axillary dissection; total mastectomy with axillary dissection and postoperative radiotherapy; and breast conserving therapy.
Estimates on future developments were based on expert interviews, international recommendations and literature (Steering Committee, 1988; Hayward & Rubens, 1987; Harris et al., 1985; Holland et al., 1985) . This resulted in the assumption that women with invasive breast carcinoma up to 3 cm in diameter, without fixed axillary lymph nodes, will undergo breast conserving therapy in the Netherlands.
Women with axillary lymph node metastases are assumed to receive adjuvant systemic therapy: CMF for premenopausal and Tamoxifen for post-menopausal women (Early Breast Cancer Trialists' Collaborative Group, 1988) . Irradiation on regional lymph nodes is assumed to depend on both lymph node metastases and tumour size.
Women with distant metastases present at first detection of breast cancer or diagnosed in the course of time are assumed to be treated for advanced disease. The policy for this treatment was based on a reported file study of 52 patients with breast cancer metastases (De Waard et al., 1986) .
Simulation model of mass screening The simulation package MISCAN was used to predict the effects of screening (Habbema et al., 1987 Especially in the start-up period, there will be an increase in the number of biopsies for non-palpable lesions of approximately 12% per year. After this period, the number of (Figure 2a and b) . Figure 2 applies to the years following the build-up period, when 26% of all women with breast cancer will be detected through screening.
The programme will also detect some 125 women each year with ductal carcinoma in situ (dCIS), which represents 1.5% of all newly diagnosed breast cancers. This carcinoma is diagnosed only occasionally in a clinical setting (Rosen, 1979; Rosner et al., 1980) . This change is important to realise because of the existing uncertainty about the natural history of dCIS (Schnitt et al., 1988) .
Changes in treatment
The total number of women to be treated with curative intent will increase as a result of screening temporarily. The more favourable stage distribution will also influence the modality used, in particular breast conserving therapy. Our analysis of hospital registries shows a moderate increase in breast conserving therapy in the years [1983] [1984] [1985] (from 9% in 1983 to 12% in 1985) . However, in recent years this development has continued. Considering the present treatment protocols we have concluded that in the near future approximately 40% of women with breast cancer will undergo breast conserving therapy if no screening is carried out. Figure 3 shows the predicted changes in treatment as a result of mass screening, compared to the situation without screening in 1994 (first column). The second column of each modality applies to the build-up period with a large number of prevalent cases (1994) (1998) . In the long run the expected increase in breast conserving therapy will be 25% per year, compared to the situation without screening. More tumours are detected with a size under 3 cm and without lymph node metastases. Consequently, the number of mastectomies (and axillary dissection) without postoperative radiotherapy will decrease by 13%. The number of women treated by mastectomy, axillary dissection and postoperative radiotherapy will decrease by 17% per year, as a result of the more favourable lymph node stage. The 8% decrease in adjuvant systemic treatment also reflects the difference in node involvement.
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In the first years of screening the change in breast conserving therapy is even 35%, as a result of the more pronounced increase in newly diagnosed cancers. This may be a relatively small increase on the total number of surgical procedures, but it will cause a strong increase for radiotherapy sessions. At present one-quarter of all new patients who need radiotherapy are breast cancer patients. On the other hand, the stage distribution of breast cancers detected at the first screening round is still less favourable compared to cancers detected in the stable situation some years after. Therefore, in the first years of the programme, the number of mastectomies will only decrease gradually.
Finally, the influence on treatment of advanced disease is important (Table I) A relative increase in breast conserving therapy of 1,400 (per one million screens) should also be considered as an asset. Although this is an intensive treatment, the higher probability of breast conservation might be one of the reasons for a woman to attend the screening. The decrease in mastectomies does not equal the increase in breast conserving therapy, as a result of the higher incidence and the detection of non-invasive lesions.
The decrease in assessment is also important. There will be a reduction in the number of biopsies with a benign histological result outside the programme, much larger than the increase in false positive biopsies from screen referrals. The preceding number of clinical mammograms will decrease too, and may be related to the increase in clinical mammograms made for screened women.
Finally, not all women will benefit from the early detection. Table II (Day & Miller, 1988) . The question remains whether good results from screening projects will also be achieved in a national setting (Day et al., 1989) . Quality control will be an important part of the programme in the Netherlands. Training of radiographers, radiologists and pathologists before the implementation of screening, and periodic evaluation of diagnostic and technical performance will be tasks of a national reference centre.
Detecting more breast cancers and non-invasive cancers Theoretically, overdiagnosis and subsequent overtreatment are important risks involved in mass screening. In practice it is difficult to assess whether overdiagnosis is actually taking place. Screening always leads to a (temporary) increase in the number of women with breast cancer, which is only a desirable effect and should not be confused with overdiagnosis. After termination of the programme one would expect a relative fall in this number.
Inevitably, some women will be detected who would, in the absence of screening, have died from other causes before the cancer had become manifest. However, this percentage is rather small; we predicted an increase in the incidence of at most 3% because of this phenomenon.
Overdiagnosis may also occur if some of the tumours would, in the absence of screening, never have progressed, or only very slowly, to a stage in which symptoms would lead to a clinical diagnosis. This may apply to ductal carcinoma in situ. In this analysis all screen-detected cancers are assumed to be progressive.
The percentages of dCIS are very similar in the major screening trials, and vary between 9% and 15% of screen-detected cancers (Tabar et al., 1985; UK Trial, 1988; Andersson et al., 1988; Hendriks, 1982) . In this respect our model fits with international data. When starting nationwide screening, this type of cancer will still remain a small fraction of the total number of diagnosed breast cancers. In view of these modest percentages, it can be concluded that even if some of these tumours would not progress or even regress, it would only result in a very small amount of overdiagnosis.
For the women invited, the fact that non-invasive carcinoma, until now treated by mastectomy, may be a nonprogressive lesion is of more (psychological) importance. Knowledge that less radical treatment for early lesions is advocated could have a positive effect on the attendance rate.
Detection rates and stage distribution
The predicted numbers of screen-detected and interval cancers are based on assumptions on pre-clinical duration and sensitivity, and are compatible with data from screening projects in Nijmegen, Utrecht and New York. These data were also found to correspond closely, adjusting for screening interval, with published data from the randomised Kopparberg/Ostergotland trial (van der Maas et al., 1988) .
Moreover, the distribution of tumour size and lymph node metastases of the detected cancers influences the predictions on assessment and treatment. The data on women with clinically diagnosed breast cancer were comparable with data from large non-screened patient groups.
In screen-detected cases, we expected 30% of the cancers to be over 20 mm at the first screen, and 15% at subsequent screens, which results in an average of 20% in the stable period (Figure 2 ). Tabar reported 26% of the cancers to have a diameter of 20 mm or more up to 1986 (Day et al., 1989 (Andersson et al., 1988; Holmberg et al., 1986) . According to Andersson, no important differences were found in the treatment of women with breast cancer between study and control group of the Malm0 trial. However, Malm0 figures do show that less women were given hormone therapy or chemotherapy in the study group. It is unclear whether the therapy trial, which was operational, has contributed to this difference.
More importantly, in the control group in Malm0 20% of the women with breast cancer underwent breast preserving therapy. In the study group, this figure was 25%, if including stage 0 tumours, and 23% if not. This means a relative increase of 15-25% compared to the control group. Because of small numbers, the difference was not statistically significant and did not seem important. But for a nationwide programme this increase in breast conserving therapy by 15-25%, when compared to the situation without screening, will have a major impact on health care facilities. The Malm0 trial seems to support our 25% increase in this type of treatment.
At least three important developments may influence the predictions on treatment. The first is the tendency to apply breast conserving therapy even in tumours over 3 cm (van Dongen et al., 1987) . Secondly, there is discussion whether radiotherapy may be omitted in some cases, e.g. in screendetected small or in situ lesions. Finally there is increasing discussion about the benefit of adjuvant systemic treatment.
Assessment outside the screening programme
Our results show that centrally organised screening will result in less biopsies than in the situation without screening. This beneficial effect will depend to a large extent on the expected change in the number of preventive mammograms after the implementation.
Many women visit their doctor for breast problems nowadays. Gravelle et al. (1982) found that 4.7% of women above 40 years of age were examined at the hospital (or undergoing a biopsy) because of breast symptoms or complaints, but no cancer was found ('worried well').
In the Malm0 trial, the control group had free access to mammography equipment outside the programme. Some 24% of women in the control group (age 45 and more) have actually had a mammogram in a mean period of 8.8 years, most only once (Andersson et al., 1988) . A percentage of 13% over a period of at most 7 years is mentioned in the Kopparberg/Ostergotland study (Tabar et al., 1985) . These figures are comparable with our estimate of 2% in the age group over 40. However, it is difficult to predict the possible decrease in preventive mammograms outside the programme, when a national screening programme is being implemented. Some 500,000 screening mammograms per year in the Netherlands will certainly cause a strong decrease in mammograms outside the programme in the age group 50-70. However, it remains uncertain how much the demand for women in other age groups will increase at the same time.
Overview
The increase in referrals and women diagnosed as having breast cancer will have its impact on workload in the first years of screening. Breast conserving therapy requires more time and effort from surgical and radiotherapy departments, and assessment of non-palpable lesions with specimen radiography and paraffin section increases the workload for pathologists. The decrease in women with advanced disease will have the opposite effect on workload only after several years. It was outside the scope of the present study to make a detailed analysis of the treatment of advanced disease.
Uncertainties remain about the attitude of women towards breast assessment outside a screening programme, and about the development of breast conserving therapy in the future.
In overview, the favourable effects of nationwide breast cancer screening outweigh the unfavourable effects. To be able to ensure these advantages, assessment and treatment should also be monitored and evaluated in a national system. The present results may enable a more balanced judgement to be made on the value of breast cancer screening and its impact on clinical medicine.
